| UHC Medicaid Medical & Drug | Long-Acting Injectable Antiretroviral Agents for HIV – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Luxturna® (Voretigene Neparvovec-Rzyl) – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Medical Therapies for Enzyme Deficiencies – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Molecular Oncology Testing for Solid Tumor Cancer Diagnosis, Prognosis, and Treatment Decisions – Community Plan Medical Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Omvoh® (Mirikizumab-Mrkz) – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Oncology Medication Clinical Coverage – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Pharmacogenetic Panel Testing – Community Plan Medical Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Roctavian® (Valoctocogene Roxaparvovec-Rvox) – Community Plan Medical Benefit Drug Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Skin and Soft Tissue Substitutes – Community Plan Medical Policy | 2026-10-01 |
| UHC Medicaid Medical & Drug | Skyrizi® (Risankizumab-Rzaa) – Community Plan Medical Benefit Drug Policy | 2026-10-01 |